Alligator Bioscience AB (publ) (ATORX.ST)
SEK 0.27
(-3.79%)
SEK 0.27
(-3.79%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 16.09 Million SEK | -34.3% |
| 2022 | 24.5 Million SEK | 151.66% |
| 2021 | 9.73 Million SEK | -19.36% |
| 2020 | 12.07 Million SEK | -29.21% |
| 2019 | 17.05 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 13.94 Million SEK | -13.38% |
| 2024 Q3 | 8.61 Million SEK | -15.53% |
| 2024 Q2 | 11.79 Million SEK | -15.42% |
| 2023 FY | 16.09 Million SEK | -34.3% |
| 2023 Q2 | 20.89 Million SEK | -10.41% |
| 2023 Q1 | 23.32 Million SEK | -4.82% |
| 2023 Q3 | 18.45 Million SEK | -11.7% |
| 2023 Q4 | 16.09 Million SEK | -12.75% |
| 2022 Q2 | 20.68 Million SEK | -7.67% |
| 2022 FY | 24.5 Million SEK | 151.66% |
| 2022 Q4 | 24.5 Million SEK | 29.33% |
| 2022 Q3 | 18.94 Million SEK | -8.43% |
| 2022 Q1 | 22.4 Million SEK | 130.14% |
| 2021 Q4 | 9.73 Million SEK | -15.46% |
| 2021 FY | 9.73 Million SEK | -19.36% |
| 2021 Q3 | 11.51 Million SEK | 36.68% |
| 2021 Q2 | 8.42 Million SEK | -28.26% |
| 2021 Q1 | 11.74 Million SEK | -2.72% |
| 2020 Q4 | 12.07 Million SEK | -5.08% |
| 2020 Q2 | 14.17 Million SEK | -9.25% |
| 2020 FY | 12.07 Million SEK | -29.21% |
| 2020 Q1 | 15.61 Million SEK | -8.43% |
| 2020 Q3 | 12.71 Million SEK | -10.25% |
| 2019 FY | 17.05 Million SEK | 0.0% |
| 2019 Q4 | 17.05 Million SEK | -6.3% |
| 2019 Q3 | 18.2 Million SEK | -5.69% |
| 2019 Q2 | 19.29 Million SEK | -6.66% |
| 2019 Q1 | 20.67 Million SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Ziccum AB (publ) | 857 Thousand SEK | -1778.296% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -223.298% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | 34.266% |
| Genovis AB (publ.) | 79.32 Million SEK | 79.706% |
| Intervacc AB (publ) | 181 Thousand SEK | -8793.37% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | 21.901% |
| Active Biotech AB (publ) | 3 Million SEK | -436.567% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | 73.306% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -221.94% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | 77.458% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | -105.634% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -3696.462% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 85.178% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -424.332% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -523.915% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -1509.7% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 98.356% |
| Camurus AB (publ) | 24.5 Million SEK | 34.317% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | 41.606% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 98.143% |
| Cyxone AB (publ) | 858 Thousand SEK | -1776.107% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -840.795% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | 56.268% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -2316.967% |
| SynAct Pharma AB | 637 Thousand SEK | -2427.002% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -1793.765% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -814.083% |
| BioInvent International AB (publ) | 23.24 Million SEK | 30.748% |
| Alzinova AB (publ) | 800 Thousand SEK | -1912.125% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 84.884% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -1982.191% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | 82.26% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | 47.519% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 93.046% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -1417.154% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |